The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have established a joint Neuroscience Cluster to enhance regulatory collaboration on medicines for neurologic and psychiatric disorders, according to terms of reference finalized on 23 January 2026 and published by EMA on 17 July 2026. The cluster aims to provide a confidential forum for exchanging scientific evaluations, policy documents, and regulatory experiences, with a focus on novel endpoints, biomarkers, clinical trial designs, and emerging therapeutic modalities.
The initiative responds to the special challenges posed by neurologic and psychiatric disorders, which are among the leading causes of disability globally. The cluster will hold monthly remote teleconferences, chaired on a rotational basis, with ad hoc meetings as needed. Participants include EMA staff from the Office for Therapies for Neurological and Psychiatric Disorders and FDA staff from the Office of Neuroscience within the Centre for Drug Evaluation and Research. Guests from other regulatory authorities may join subject to confidentiality arrangements.
By fostering early and regular dialogue, the cluster is expected to accelerate the development of effective treatments for conditions such as Alzheimer's disease, Parkinson's disease, depression, and schizophrenia. For patients, this could mean faster access to innovative therapies. For pharmaceutical companies, the cluster may reduce duplication of efforts and provide clearer regulatory pathways, potentially lowering development costs. However, the confidential nature of the exchanges may limit transparency for other stakeholders, including patient groups and academic researchers, who will not have direct insight into the discussions. National regulatory agencies in EU member states may also face challenges in aligning with EMA-FDA positions developed within the cluster.
The terms of reference do not specify a fixed duration for the cluster, indicating a long-term commitment to ongoing collaboration.